Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase
合成生物制品公司宣布前6名参与者服用SYN-020肠道碱性磷酸酶1a期临床试验
Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase ("IAP").
合成生物制品公司(纽约证券交易所：同步)，一家利用微生物群开发治疗药物的多元化临床阶段公司，旨在预防和治疗高需求地区的胃肠道(GI)疾病，该公司今天宣布，已开始招募，6名研究参与者参加了SYN-020肠道碱性磷酸酶(“IAP”)的第1阶段单剂量递增临床试验。